一分钟看懂
这是一项关于腺癌的III 期研究，登记的药物或干预包括Cadonilimab；CAPOX regimen；Nivolumab；Placebo，当前状态为招募中。登记地点显示中国北京、广州、上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Cadonilimab；CAPOX regimen；Nivolumab；Placebo · III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出7项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Friendship Hospital, Capital Medical University · 北京
- Peking University Cancer Hospital, Gastrointestinal Cancer Center I · 北京
- Peking University Cancer Hospital, Gastrointestinal Oncology · 北京
- Guangdong Provincial People's Hospital · 广州
- Zhongshan Hospital Fudan University · 上海
公开的入选条件
- 1. Able to provide written informed consent and can understand and comply with the requirements of the study.
- 2. Histopathologically-confirmed diagnosis of locally advanced unresectable or metastatic G/GEJ adenocarcinoma.
- 3. No prior systemic therapy for locally advanced unresectable or metastatic G/GEJ adenocarcinoma. NOTE: For participants who have received prior neoadjuvant/adjuvant therapy for curative intent, the time between disease progression and last treatment should b
- 4. ECOG PS of 0 or 1 within 3 days prior to randomization.
- 5. Age ≥ 18 years at the time of voluntarily signing informed consent.
- 6. Evaluable PD-L1 expression results.
- 7. Participants must have at least one measurable lesion per RECIST v1.1 as assessed by investigator assessment. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- 8. Adequate organ function as indicated by the following laboratory values. Specimens must be collected within 7 days prior to the first dose of study treatment.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07700979；登记信息更新于 2026-09-29。